Abstract 183P
Background
The incidence of gastric cancer is particularly high in Iran, where it remains a leading cause of cancer-related death, and it is the most common cancer among Iranian men, with an ASR of 21.6 per 100,000 men (GLOBO2018). By contrast the incidence and mortalityof gastric cancer rank fifth and third respectively worldwide. The aim of this study was to evaluate the epidemiologic profile of gastric cancer in East Azerbaijan, Iran.
Methods
In total, 2 years of cancer registry data were collected from different sources in East Azerbaijan (EA-PBCR), and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, with data were generated for each year from 1394 to 1395 of the Persian calendar (i.e., 19 March 2015 to 20 March 2016).
Results
In total we registered 1700 gastric cancer in two years; 918 cases in 2015 and 712 cases in 2016. From these, 1181 cases were male and 519 cases were female, and the male to female ratio was 2.28. The mean age of the patients was 68.45 (±12.97) years, with age range of 21-99 years old. The most common age group was 7th decade with 531 (31.2%) gastric cancer cases. The most common morphological types were adenocarcinoma (n = 667, 39.2%), and intestinal type carcinoma (n = 421, 24.8%), and signet ring cell carcinoma (n = 119, 7%). The age standardized incidence rate (ASR) was 29.65 and 13.30 in males and females per 100,000, in 2015. The ASR was 26.48 and 9.91 in males and females per 100,000, in 2016. Gastric Cancer account for 12.4% of all cancers in both sexes, and the odds for men was 1.50, compared with women (OR 1.50; 95% CI = 1.33 – 1.71). After rigorous attempts, 63.5 % of the cases had microscopic verification (MV), and we collected 3.3 % of reports based on clinical data. The remaining data were collected from the cause of death registry or autopsy records, producing a final DCO% of 27.4%.
Conclusions
The ASR was decreased from 29.7 to 26.48 in men, and decreased from 13.3 to 9.91 in female. However gastric cancer is the most common cancer in terms of incidence and mortality in East Azerbaijan, according to last results of EA-PBCR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract